Trevi Therapeutics Secures FDA Alignment for Pivotal Phase 3 IPF Cough Trials; Reports Strong Cash Runway

summarizeSummary

Trevi Therapeutics announced critical FDA alignment for its Phase 3 program in IPF-related chronic cough, detailed plans for multiple new clinical trial initiations, and reported a strong financial position with cash runway into 2028.

check_boxKey Events

• FDA Alignment for Pivotal Phase 3 Program

  The company achieved overall alignment with the FDA on the development plan for Haduvio™ (oral nalbuphine ER) for IPF-related chronic cough, including the design of two pivotal Phase 3 clinical trials.

• Initiation of Phase 3 Trials

  Trevi Therapeutics is on track to initiate the first pivotal Phase 3 trial for IPF-related chronic cough in Q2 2026, followed by the second Phase 3 trial in H2 2026.

• Expanded Clinical Pipeline

  Plans are in place to initiate a Phase 2b trial for refractory chronic cough (RCC) in Q2 2026 and an adaptive design Phase 2b trial for non-IPF ILD-related chronic cough in H2 2026.

• Strong Financial Position

  The company ended 2025 with $188.3 million in cash, cash equivalents, and marketable securities, providing an expected cash runway into 2028.

auto_awesomeAnalysis

This filing is highly significant for Trevi Therapeutics, a clinical-stage biopharmaceutical company. The most critical update is the successful End-of-Phase 2 meeting with the FDA, which resulted in overall alignment on the development program for IPF-related chronic cough, including the design and initiation timeline for two pivotal Phase 3 clinical trials. This de-risks the regulatory pathway significantly and provides a clear path towards potential commercialization. Furthermore, the company's strong financial position, with $188.3 million in cash and a projected runway into 2028, provides ample capital to fund these extensive clinical programs without immediate dilution concerns. The planned initiation of multiple Phase 2b trials for other chronic cough indications also demonstrates a robust and advancing pipeline. Investors should view this as a strong positive signal, indicating significant progress in its lead program and solid financial footing.